Lv29
110 积分 2026-04-13 加入
Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial
4天前
已完结
SMARCA4 pathogenic variants: Gynecological cancer histories from a laboratory tested cohort
5天前
已完结
We Asked the Experts: Minimally Invasive Segmentectomy for Early Stage Lung Cancer—Will it Replace Lobectomy?
5天前
已完结
Potential of Minimal Residual Disease in Guiding Adjuvant Therapy Decisions in Non–Small Cell Lung Cancer
6天前
已完结
First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trial
11天前
已完结
Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non–Small-Cell Lung Cancer With EGFR Mutation (IMPACT)
1个月前
已完结
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study
1个月前
已完结
Icotinib versus chemotherapy as adjuvant treatment for stage II–IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial
1个月前
已完结
Propensity-matched analysis of adjuvant chemotherapy for completely resected Stage IB non-small-cell lung cancer patients
1个月前
已完结
Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of people with resected stage I to III non-small-cell lung cancer and EGFR mutation
1个月前
已完结
皖公网安备34019202002308
